688235:SHA
BeOne Medicines AG
၂၅၉.၃၇ CN¥
arrow_upward
+၁.၃၂%(+၃.၃၉) 1D
အောက် ၁၉, GMT+၈ ၁၅:၀၀:၀၀ · CNY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 688235...
Open
၂၅၃.၀၀ CN¥
High
၂၆၁.၈၄ CN¥
Low
၂၅၃.၀၀ CN¥
Mkt. cap
ဋေ ၃.၀၃ သ
Avg. vol.
၂.၉၃ သန်း
Volume
၂.၈၂ သန်း
P/E ratio
၉၂.၆၄
52-wk high
၃၁၉.၂၄ CN¥
52-wk low
၂၀၅.၅၁ CN¥
EPS
၂.၈၀ CN¥
No. of employees
၁ သောင်း
Open
၂၅၃.၀၀ CN¥
High
၂၆၁.၈၄ CN¥
Low
၂၅၃.၀၀ CN¥
Mkt. cap
ဋေ ၃.၀၃ သ
Avg. vol.
၂.၉၃ သန်း
Volume
၂.၈၂ သန်း
P/E ratio
၉၂.၆၄
52-wk high
၃၁၉.၂၄ CN¥
52-wk low
၂၀၅.၅၁ CN¥
EPS
၂.၈၀ CN¥
No. of employees
၁ သောင်း
News stories
From web sources and news partners
MarketBeat
·
ပြီးခဲ့သည့် ၃ ရက်
BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,027 Shares
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees၁.၂ သောင်း
Founded၂၀၁၀ အောက် ၂၈
Headquarters-
Sector-
Websitebeonemedicines.com